Novavax, Inc. (NASDAQ:NVAX) Q2 2024 Results Conference Call August 8, 2024 8:30 AM ET

Company Participants

Erika Schultz - Senior Director of Investor Relations
John Jacobs - President and Chief Executive Officer
John Trizzino - President and Chief Operating Officer
Dr. Bob Walker - Chief Medical Officer and Interim Head of Research and Development
Jim Kelly - Chief Financial Officer and Treasurer

Conference Call Participants

Roger Song - Jefferies
Mayank Mamtani - B. Riley Securities
Alec Stranahan - Bank of America
Eric Joseph - JPMorgan

Operator

Good morning, and welcome to Novavax' Second Quarter 2024 Financial Results and Operational Highlights Conference Call. All participants will be in a listen-only mode. [Operator Instructions]. Please note this event is being recorded.

I would now like to turn the call over to Erika Schultz, Senior Director, Investor Relations. Please go ahead.

Erika Schultz

Good morning, and thank you all for joining us today to discuss our second quarter 2024 financial results and operational highlights. A press release announcing our results is currently available on our website at novavax.com, and an audio archive of this conference call will be available on our website later today.

Please turn to Slide 2. Before we begin with prepared remarks, I need to remind you that, this presentation includes forward-looking statements, including information relating to the future of Novavax. Its key strategic priorities, statements related to potential royalties and milestones, operating plans, objectives and prospects, full year 2024 financial guidance, the amount and impact of Novavax' cost reduction plans, its future financial or business performance conditions or strategies, its partnerships, anticipated timing and outcome of future regulatory filings and actions, and the ongoing development, marketing opportunities, manufacturing capacity and future availability of our vaccine candidates, and key upcoming milestones.

Each forward-looking statement contained in this presentation is subject to risks and uncertainties that could cause actual results to differ materially from those projected in such statements. Additional information regarding these factors appears under the heading Cautionary Note regarding forward-looking statements in the slide deck we issued this morning and under the heading Risk Factors in our most recent Form 10-K and subsequent Form 10-Qs, filed with the Securities and Exchange Commission available at www.sec.gov and on our website at novavax.com. The forward-looking statements in this presentation speak only as of the original date of this presentation, and we undertake no obligation to update or revise any of these statements.